@article{230df0b5d0e44be2bfa7d96c9c23541f,
title = "Prolactin and endocrine therapy resistance in breast cancer: The next potential hope for breast cancer treatment",
abstract = "Breast cancer, a hormone-dependent tumour, generally includes four molecular subtypes (luminal A, luminal B, HER2 enriched and triple-negative) based on oestrogen receptor, progesterone receptor and human epidermal growth factor receptor-2. Multiple hormones in the body regulate the development of breast cancer. Endocrine therapy is one of the primary treatments for hormone-receptor-positive breast cancer, but endocrine resistance is the primary clinical cause of treatment failure. Prolactin (PRL) is a protein hormone secreted by the pituitary gland, mainly promoting mammary gland growth, stimulating and maintaining lactation. Previous studies suggest that high PRL levels can increase the risk of invasive breast cancer in women. The expression levels of PRL and PRLR in breast cancer cells and breast cancer tissues are elevated in most ER+ and ER− tumours. PRL activates downstream signalling pathways and affects endocrine therapy resistance by combining with prolactin receptor (PRLR). In this review, we illustrated and summarized the correlations between endocrine therapy resistance in breast cancer and PRL, as well as the pathophysiological mechanisms and clinical practices. The study on PRL and its receptor would help explore reversing endocrine therapy-resistance for breast cancer.",
keywords = "breast cancer, endocrine therapy, prolactin, prolactin receptor, resistance, review",
author = "Yuan Li and Xiangyi Kong and Lixue Xuan and Zhongzhao Wang and Huang, {Yen Hua}",
note = "Funding Information: Cancer Institute and Hospital, Chinese Academy of Medical Sciences 2019HX320067. This work was supported by the Natural Science Foundation of China (No. 82103047), the Beijing Municipal Natural Science Foundation (No. 7204293), the Special Research Fund for Central Universities, Peking Union Medical College (No. 3332019053), the Beijing Hope Run Special Fund of Cancer Foundation of China (No. LC2019B03), the Golden Bridge Project Seed Fund of Beijing Association for Science and Technology (No. ZZ20004), the 2021 Chaoyang District Social Development Science and Technology Plan Project (Medical and Health Field) (No. CYSF2115), the Chinese Young Breast Experts Research project (No. CYBER-2021-005), the XianSheng Clinical Research Special Fund of China International Medical Foundation (No. Z-2014-06-2103), and the Beijing Xisike Clinical Oncology Research Foundation (No. Y-Young2021-0017) Not applicable. Funding Information: Cancer Institute and Hospital, Chinese Academy of Medical Sciences 2019HX320067. This work was supported by the Natural Science Foundation of China (No. 82103047), the Beijing Municipal Natural Science Foundation (No. 7204293), the Special Research Fund for Central Universities, Peking Union Medical College (No. 3332019053), the Beijing Hope Run Special Fund of Cancer Foundation of China (No. LC2019B03), the Golden Bridge Project Seed Fund of Beijing Association for Science and Technology (No. ZZ20004), the 2021 Chaoyang District Social Development Science and Technology Plan Project (Medical and Health Field) (No. CYSF2115), the Chinese Young Breast Experts Research project (No. CYBER‐2021‐005), the XianSheng Clinical Research Special Fund of China International Medical Foundation (No. Z‐2014‐06‐2103), and the Beijing Xisike Clinical Oncology Research Foundation (No. Y‐Young2021‐0017) Publisher Copyright: {\textcopyright} 2021 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.",
year = "2021",
month = nov,
doi = "10.1111/jcmm.16946",
language = "English",
volume = "25",
pages = "10327--10348",
journal = "Journal of Cellular and Molecular Medicine",
issn = "1582-1838",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "22",
}
